Invasive pneumococcal disease: Association between serotype, clinical presentation and lethality

Vaccine

Volumn 29, Issue 34, 2011, Pages 5740-5746

  Rodríguez, M Angeles Gutiérrez ^a   González, Amai Varela ^a   Gavín, María Ascensión Ordobás ^a   Martínez, Fernando Martín ^a   Marín, Natividad García ^a   Blázquez, Belén Ramos ^b   Moreno, Juan Carlos Sanz ^b  

^a Subdirección de Promoción de la Salud y Prevención   (Spain)

^b Unidad de Microbiología Clínica Laboratorio Regional de Salud Pública Comunidad de Madrid   (Spain)

Author keywords

Heptavalent pneumococcal conjugate vaccine; Invasive pneumococcal disease; Serotype

Indexed keywords

PNEUMOCOCCUS VACCINE;

ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL FEATURE; DISEASE ASSOCIATION; FEMALE; HOSPITAL PATIENT; HUMAN; LETHALITY; MAJOR CLINICAL STUDY; MALE; MORBIDITY; PNEUMOCOCCAL INFECTION; PRESCHOOL CHILD; PRIORITY JOURNAL; RISK FACTOR; SCHOOL CHILD; SEPSIS; SEROTYPE;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; IMMUNIZATION; INFANT; MALE; MIDDLE AGED; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; POPULATION SURVEILLANCE; SEROTYPING; STREPTOCOCCUS PNEUMONIAE;

EID: 79960509685     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.05.099     Document Type: Article

References (43)

1. WHO 23-Valent pneumococcal polysaccharide vaccine WHO position paper. Wkly Epidemiol Rec 2008, 83(42):373-384. http://www.who.int/wer.
2. Pebody R.G., Hellenbrand W., D'Ancona F., Ruutu P. Pneumococcal disease surveillance in Europe. Euro Surveill 2006, 11(9):171-178. on behalf of the European Union funded Pnc-EURO contributing group.
3. Musher D.M. Streptococcus pneumoniae Enfermedades infecciosas. Principios y práctica. Mandell, Douglas y Bennett 2006, Elsevier España SA, Madrid. 6th ed.
4. Kuch A., Sadowy E., Skoczyńska A., Hryniewicz W. First report of Streptococcus pneumoniae serotype 6D isolates from invasive infections. Vaccine 2010, 28:6406-6407.
5. Hausdorff W.P., Siber G., Paradiso P.R. Geographical differences in invasive pneumococcal disease rates and serotype frequency in young children. The Lancet 2001, 357:950-952.
6. Hausdorff W.P., Feikin D.R., Klugman K.P. Epidemiological differences among pneumococcal serotypes. Lancet Infect Dis 2005, 5:83-93.
7. Roberts J., Chandra M., Pebody R., Stuart J. Variation in incidence of pneumococcal and meningococcal disease across Europe. Euro Surveill 2007, 12(November (11)):E071115.5. http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=3310.
8. Roche P.W., Krause V., Cook H., Barralet J., Coleman D., Sweeny A., et al. Invasive pneumococcal disease in Australia, 2006. Commun Dis Intell 2008, 32(1):18-30.
9. Center for Disease Control and Prevention. 2010. Active bacterial core surveillance (ABCs) report. Emerging infections program network, Streptococcus pneumoniae, provisional-2009. http://www.cdc.gov/ncidod/dbmd/abcs/survreports/spneu09.pdf.
10. Vergison A., Tuerlinckx D., Verhaegen J., Malfroot A. Epidemiologic features of invasive pneumococcal disease in Belgian children: passive surveillance is not enough. Pediatrics 2006, 118(3):e801-e809. Belgian Invasive Pneumococcal Disease Study Group.
11. McIntosh E.D., Fritzell B., Fletcher M.A. Burden of paediatric invasive pneumococcal disease in Europe, 2005. Epidemiol Infect 2007, 135(4):644-656.
12. Trotter C.L., Waight P., Andrews N.J., Slack M., Efstratiou A., George R., et al. Epidemiology of invasive pneumococcal disease in the pre-conjugate vaccine era: England and Wales 1996-2006. J Infect 2010, 60:200-208.
13. Jefferson T., Ferroni E., Curtale F., Rossi P.G., Borgia P. Streptococcus pneumoniae in western Europe: serotype distribution and incidence in children less than 2 years old. Lancet Infection Dis 2006, 6:405-410.
14. Aristegui J., Bernaola E., Pocheville I., García C., Arranz L., Durán G., et al. Reduction in paediatric invasive pneumococcal disease in the Basque Country and Navarre, Spain, after the introduction of the heptavalent pneumococcal vaccine. Eur J Clin Microbiol Infect Dis 2007, 26:303-310.
15. Hanquet G., Perrocheau A., Kissling E., Bruhl D.L., Tarragó D., Stuart J., et al. Surveillance of invasive pneumococcal disease in 30 EU countries: towards a European system?. Vaccine 2010, 28:3920-3928.
16. Barricarte A., Castilla J., Gil-Setas A., Torroba L., Navarro-Alonso J.A., Irisarri F., et al. Effectiveness of the 7-valent pneumococcal conjugate vaccine: a population-based case-control study. Clin Infect Dis 2007, 44(11):1436-1441.
17. Vestrheim D.F., Løvoll O., Aaberge I.S., Caugant D.A., Høiby E.A., Bakke H., et al. Effectiveness of a 2+1 dose schedule pneumococcal conjugate vaccination programme on invasive pneumococcal disease among children in Norway. Vaccine 2008, 26(26):3277-3281.
18. Oosterhuis-Kafeja F., Beutels P., Van Damme P. Immunogenicity, efficacy, safety and effectiveness of pneumococcal conjugate vaccines (1998-2006). Vaccine 2007, 25(12):2194-2212.
19. Pilishvili T., Lexau C., Farley M.M., Hadler J., Harrison L.H., Bennett M.N., et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. JID 2010, 201:32-41.
20. Harboe Z.B., Valentiner-Branth P., Nenfield T.L., Christensen J.J., Ansersen P.H., Howitz M., et al. Early effectiveness of heptavalent conjugate pneumococcal vaccination on invasive pneumococcal disease after the introduction in the Danish childhood immunization programme. Vaccine 2010, 28:2642-2647.
21. Fenoll A., Granizo J.J., Aguilar L., Giménez M.J., Aragoneses-Fenoll L., Hanquet G., et al. Temporal trends of invasive Streptococcus pneumoniae serotypes and antimicrobial resistence patterns in Spain from 1979 to 2007. J Clin Microbiol 2009, 47:1012-1020.
22. Isaacman D.J., McIntosh E.D., Reinert R.R. Burden of invasive pneumococcal disease and serotype distribution among Streptococcus pneumoniae isolates in young children in Europe: impact of the 7-valent pneumococcal conjugate vaccine and considerations for future conjugate vaccines. Int J Infect Dis 2010, 14(3):e197-e209.
23. Romney M.G., Hull M.W., Gustafson R., Sandhu J., Champagne S., Wong T., et al. Large community outbreak of Streptococcus pneumoniae serotype 5 invasive infection in an impoverished, urban population. Clin Infect Dis 2008, 47:768-774.
24. Grijalva C.G., Nuorti J.P., Arbogast P.G., Martin S.W., Edwards K.M., Griffin M.R. Decline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the USA: a time-series analysis. Lancet 2007, 369(9568):1179-1186.
25. Whitney C.G., Farley M.M., Hadler J., Harrison L.H., Bennett N.M., Lynfield R., et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med 2003, 348(18):1737-1746.
26. Muñoz-Almagro C., Jordan I., Gene A., Latorre C., Garcia-Garcia J.J., Pallares R. Emergence of invasive pneumococcal disease caused by nonvaccine serotypes in the era of 7-valent conjugate vaccine. Clin Infect Dis 2008, 46(2):174-182.
27. Hicks L.A., Harrison L.H., Flannery B., Hadler J.L., Schaffner W., Craig A.S., et al. Incidence of pneumococcal disease due to non-pneumococcal conjugate vaccine (PCV7) serotypes in the United States during the era of widespread PCV7 vaccination, 1998-2004. J Infect Dis 2007, 196(9):1346-1354.
28. Byington C.L., Samore M.H., Stoddard G.J., Barlow S., Daly J., Korgenski K., et al. Temporal trends of invasive disease due to Streptococcus pneumoniae among children in the intermountain west: emergence of nonvaccine serogroups. Clin Infect Dis 2005, 41(1):21-29.
29. Kaplan S.L., Mason E.O., Wald E.R., Schutze G.E., Bradley J.S., Tan T.Q., et al. Decrease of invasive pneumococcal infections in children among 8 children's hospitals in the United States after the introduction of the 7-valent pneumococcal conjugate vaccine. Pediatrics 2004, 113(3 Pt 1):443-449.
30. Kaplan S.L., Barson W.J., Lin P.L., Stovall S.H., Bradley J.S., Tan T.Q., et al. Serotype 19A is the most common serotype causing invasive pneumococcal infections in children. Pediatrics 2010, 125(3):429-436.
31. Weinberger D.M., Harboe Z.B., Sanders E.A.M., Ndiritu M., Klugman K.P., Rükinger S., et al. Association of serotype with risk of death due a pneumococcal pneumoniae: a meta-analysis. Clin Infect Dis 2010, 51:692-699.
32. Sjöström K., Spindler C., Ortqvist A., Kalin M., Sandgren A., Kühlmann-Berenzon S., et al. Clonal and capsular types decide whether pneumococci will act as a primary or opportunistic pathogen. Clin Infect Dis 2006, 42:451-459.
33. Martens P., Worm S.W., Lundgren B., Konradsen H.B., Benfield T. Serotype-specific mortality from invasive Streptococcus pneumoniae disease revisited. BMC Infect Dis 2004, 4:21.
34. Harboe Z.B., Thomsen R.W., Riis A., Valentiner-Branth P., Christensen J.J., Lambertsen L., et al. Pneumococcal serotypes and mortality following invasive pneumococcal disease: a population-based cohort study. PLoS Med 2009, 6(5):e1000081. [Epub 2009 May 26].
35. Jansen A.G., Rodenburg G.D., Van der Ende A., Van Alphen L., Veenhoven R.H., Spanjaard L., et al. Invasive pneumococcal disease among adults: associations among serotypes, disease characteristics, and outcome. Clin Infect Dis 2009, 49(July (2)):e23-e29.
36. Pletz M.W., Welte T., Klugman K.P. The paradox in pneumococcal serotypes: highly invasive does not mean highly lethal. Eur Respir J 2010, 36(4):712-713.
37. Henriques B., Kalin M., Ortqvist A., Liljequist B.O., Almela M., Marrie T.J., et al. Molecular epidemiology of Streptococcus pneumoniae causing invasive disease in 5 countries. J Infect Dis 2000, 182:833-839.
38. Picazo J., Ruiz-Contreras J., Casado-Flores J., Giangaspro E., Del Castillo F., Hernández-Sampelayo T., et al. Relationship between serotypes, age, and clinical presentation of Invasive pneumococcal Disease in Madrid, Spain, after introduction of 7-valent pneumococcal conjugate vaccine into the vaccination calendar. Clin Vaccine Immunol 2011, 18(1):89-94.
39. Fenoll A., Aguilar L., Vicioso M.D., Gimenez M.J., Granizo J.J., Mendez C. Serotype distribution and susceptibility of Streptococcus pneumoniae isolates from pleural fluid in Spain from 1997 to 2008. Antimicrob Agents Chemother 2010, 54(12):5387-5390.
40. Obando I., Muñoz-Almagro C., Arroyo L.A., Tarrago D., Sanchez-Tatay D., Moreno-Perez D., et al. Pediatric parapneumonic empyema, Spain. Emerg Infect Dis 2008, 14:1390-1417.
41. Phoeling K.A., Talbot T.R., Griffin M.R., Craig A.S., Whitney C.G., Zell E., et al. Invasive pneumococcal disease among infants before and after introduction of pneumococcal conjugate vaccine. JAMA 2006, 295:1668-1674.
42. Aguiar S.I., Brito M.J., Gonçalo-Marques J., Ramirez M. Serotypes 1, 7F, and 19A became the leading causes of pediatric invasive pneumococcal infections in Portugal after 7 years of heptavalent conjugate vaccine use. Vaccine 2010, 28:5166-5173.
43. Reinert R.R., Jacobs M.R., Kaplan S.L. Pneumococcal disease caused by serotype 19A: review of the literature and implications for future vaccine development. Vaccine 2010, 28:4249-4259.